Binding of fusion protein FLSC IgG1 to CCR5 is enhanced by CCR5 antagonist Maraviroc

被引:5
|
作者
Latinovic, Olga [1 ,2 ]
Schneider, Kate [1 ,2 ]
Szmacinski, Henryk [3 ]
Lakowicz, Joseph R. [3 ]
Heredia, Alonso [1 ,4 ]
Redfield, Robert R. [1 ,4 ]
机构
[1] Univ Maryland, Sch Med, Inst Human Virol, Baltimore, MD 21201 USA
[2] Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA
[3] Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA
[4] Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA
关键词
HIV-1; CCR5; antagonist; Maraviroc; Fusion protein; HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-1; CHEMOKINE; TYPE-1; EXPRESSION; ENTRY; ANTIBODY; CELLS; CD4; INFECTIONS;
D O I
10.1016/j.antiviral.2014.10.006
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The CCR5 chemokine receptor is crucial for human immunodeficiency virus type 1 (HIV-1) infection, acting as the principal coreceptor for HIV-1 entry and transmission and is thus an attractive target for antiviral therapy. Studies have suggested that CCR5 surface density and its conformational changes subsequent to virion engagement are rate limiting for entry, and consequently, infection. Not all CCR5 antibodies inhibit HIV-1 infection, suggesting a need for more potent reagents. Here we evaluated full length single chain (FLSC) IgG1, a novel IgG-CD4-gp12(BAL) fusion protein with several characteristics that make it an attractive candidate for treatment of HIV-1 infections, including bivalency and a potentially increased serum half-life over FLSC, the parental molecule. FLSC IgG1 binds two domains on CCR5, the N-terminus and the second extracellular loop, lowering the levels of available CCR5 viral attachment sites. Furthermore, FLSC IgG1 synergizes with Maraviroc (MVC), the only licensed CCR5 antagonist. In this study, we used both microscopy and functional assays to address the mechanistic aspects of the interactions of FLSC IgG1 and MVC in the context of CCR5 conformational changes and viral infection. We used a novel stochastic optical reconstruction microscopy (STORM), based on high resolution localization of photoswitchable dyes to visualize direct contacts between FLSC IgG1 and CCR5. We compared viral entry inhibition by FLSC IgG1 with that of other CCR5 blockers and showed FLSC IgG1 to be the most potent. We also showed that lower CCR5 surface densities in HIV-1 infected primary cells result in lower FLSC IgG1 EC50 values. In addition, CCR5 binding by FLSC IgG1, but not CCR5 Ab 2D7, was significantly increased when cells were treated with MVC, suggesting MVC allosterically increases exposure of the FLSC IgG1 binding site. These data have implications for future antiviral therapy development. (C) 2014 Elsevier B.V. All rights reserved.
引用
收藏
页码:80 / 90
页数:11
相关论文
共 50 条
  • [21] Use of maraviroc, the first CCR5 receptor antagonist, in HIV treatment regimens
    Kravchenko, A. V.
    TERAPEVTICHESKII ARKHIV, 2013, 85 (11) : 125 - +
  • [22] Overcoming hERG affinity in the discovery of maraviroc; A CCR5 antagonist for the treatment of HIV
    Price, David A.
    Armour, Duncan
    de Groot, Marcel
    Leishman, Derek
    Napier, Carolyn
    Perros, Manos
    Stammen, Blanda L.
    Wood, Anthony
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2008, 8 (13) : 1140 - 1151
  • [23] Maraviroc, a CCR5 antagonist, prevents development of hepatocellular carcinoma in a mouse model
    Ochoa-Callejero, Laura
    Perez-Martinez, Laura
    Rubio-Mediavilla, Susana
    Oteo, Jose A.
    Martinez, Alfredo
    Blanco, Jose R.
    CANCER RESEARCH, 2012, 72
  • [24] Analysis of binding sites for the new small-molecule CCR5 antagonist TAK-220 on human CCR5
    Nishikawa, M
    Takashima, K
    Nishi, T
    Furuta, RA
    Kanzaki, N
    Yamamoto, Y
    Fujisawa, J
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (11) : 4708 - 4715
  • [25] Glycans are involved in RANTES binding to CCR5 positive as well as to CCR5 negative cells
    Mbemba, E
    Slimani, H
    Atemezem, A
    Saffar, L
    Gattegno, L
    BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 2001, 1510 (1-2): : 354 - 366
  • [26] The role of the gene CCR5 polymorphisms CCR5Δ32 e CCR5 59029 in ocular toxoplasmosis.
    Faria Junior, G. M.
    Ayo, C. M.
    Murata, F. H. A.
    Frederico, F. B.
    Lopes, A. G.
    Oliveira, A. P.
    de Mattos, L. C.
    de Mattos, C. C. B.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2018, 73 : 110 - 110
  • [27] Maraviroc, a CCR5 Coreceptor Antagonist That Blocks Entry of Human Immunodeficiency Virus Type 1
    Hunt, Joshua S.
    Romanelli, Frank
    PHARMACOTHERAPY, 2009, 29 (03): : 295 - 304
  • [28] CCR5 binding properties of a CCR5 small-molecule inhibitor with high antiviral potency against a maraviroc-resistant HIV-1 strain
    Jekle, A.
    Kondru, R.
    Ji, C.
    Chuang, K-T
    Swinney, D. C.
    Rotstein, D.
    Sankuratri, S.
    Cammack, N.
    Heilek, G.
    ANTIVIRAL THERAPY, 2007, 12 (05) : S13 - S13
  • [29] Profile of maraviroc: a CCR5 antagonist in the management of treatment-experienced HIV patients
    Lorenzen, Thore
    HIV AIDS-RESEARCH AND PALLIATIVE CARE, 2010, 2 : 151 - 156
  • [30] Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers
    Abel, Samantha
    van der Ryst, Elna
    Rosario, Maria C.
    Ridgway, Caroline E.
    Medhurst, Christine G.
    Taylor-Worth, Richard J.
    Muirhead, Gary J.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 65 : 5 - 18